These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 10399472)

  • 1. [Pleural mesothelioma. A case report].
    Della Vittoria Scarpati M; Parascandolo V; Santini M; Di Crescenzo VG; Di Lieto E; Vicidomini G
    Recenti Prog Med; 1999 Jun; 90(6):327-30. PubMed ID: 10399472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The clinical picture and therapy of malignant pleural mesothelioma].
    Schiebe M; Hoffmann W; Kortmann RD; Bamberg M
    Strahlenther Onkol; 1994 Nov; 170(11):628-35. PubMed ID: 7526476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative assessment and therapeutic options for patients with malignant pleural mesothelioma.
    Paul S; Neragi-Miandoab S; Jaklitsch MT
    Thorac Surg Clin; 2004 Nov; 14(4):505-16, ix. PubMed ID: 15559057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trials in malignant pleural mesothelioma in Australasia.
    Nowak AK
    Lung Cancer; 2005 Jul; 49 Suppl 1():S113-6. PubMed ID: 15950790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of malignant pleural mesothelioma.
    West SD; Lee YC
    Clin Chest Med; 2006 Jun; 27(2):335-54. PubMed ID: 16716822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
    Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
    In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma.
    Lucchi M; Chella A; Melfi F; Dini P; Ambrogi M; Fino L; Fontanini G; Mussi A
    Eur J Cardiothorac Surg; 2007 Mar; 31(3):529-33; discussion 533-4. PubMed ID: 17188885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Current insights in malignant pleural mesothelioma].
    Bard M; Debrosse D; Caliandro R; Girard P; Grunenwald D; Ruffié P
    Bull Cancer; 2002 Jan; 89(1):67-74. PubMed ID: 11847028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant mesothelioma 2008.
    Zervos MD; Bizekis C; Pass HI
    Curr Opin Pulm Med; 2008 Jul; 14(4):303-9. PubMed ID: 18520263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. May cyclooxygenase-2 (COX-2), p21 and p27 expression affect prognosis and therapeutic strategy of patients with malignant pleural mesothelioma?
    Mineo TC; Ambrogi V; Cufari ME; Pompeo E
    Eur J Cardiothorac Surg; 2010 Sep; 38(3):245-52. PubMed ID: 20338775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged survival after talc poudrage for malignant pleural mesothelioma: case series.
    Aelony Y; Yao JF
    Respirology; 2005 Nov; 10(5):649-55. PubMed ID: 16268920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinicopathological study of 23 pleural malignant mesotheliomas].
    Bombí JA; Xaubet A; Letang E; Ribalta T; Picado C; Agustí Vidal A; Sánchez-Lloret J; Cardesa A
    Rev Clin Esp; 1988 May; 182(9):464-70. PubMed ID: 3175139
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of malignant pleural mesothelioma--present status and future view].
    Yano T; Morodomi Y; Ito K; Miura N; Takenaka T; Kawano D; Shoji F; Maehara Y
    Fukuoka Igaku Zasshi; 2008 Apr; 99(4):74-9. PubMed ID: 18646592
    [No Abstract]   [Full Text] [Related]  

  • 14. [Malignant pleural mesothelioma: early diagnosis and multimodality management].
    Pavia R; Mondello B; Barone M; Surleti S; Puliafito M; Barresi P
    G Chir; 2005; 26(6-7):257-60. PubMed ID: 16332304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consensus report: pretreatment minimal staging and treatment of potentially resectable malignant pleural mesothelioma.
    van Meerbeeck JP; Boyer M
    Lung Cancer; 2005 Jul; 49 Suppl 1():S123-7. PubMed ID: 15950792
    [No Abstract]   [Full Text] [Related]  

  • 16. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy.
    Kao SC; Pavlakis N; Harvie R; Vardy JL; Boyer MJ; van Zandwijk N; Clarke SJ
    Clin Cancer Res; 2010 Dec; 16(23):5805-13. PubMed ID: 20956618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Malignant pleural mesothelioma: causes, diagnosis and treatment].
    Bahm J; Knauf M; Bohndorf K
    Dtsch Med Wochenschr; 1990 Mar; 115(13):508-13. PubMed ID: 2180673
    [No Abstract]   [Full Text] [Related]  

  • 18. High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma.
    Halme M; Knuuttila A; Vehmas T; Tammilehto L; Mäntylä M; Salo J; Mattson K
    Br J Cancer; 1999 Aug; 80(11):1781-5. PubMed ID: 10468296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes.
    Ribi K; Bernhard J; Schuller JC; Weder W; Bodis S; Jörger M; Betticher D; Schmid RA; Stupp R; Ris HB; Stahel RA;
    Lung Cancer; 2008 Sep; 61(3):398-404. PubMed ID: 18433927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of malignant pleural mesothelioma].
    Köksal D; Beder S
    Tuberk Toraks; 2003; 51(3):310-9. PubMed ID: 15143412
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.